EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors

Neeraj Chhabra iD, Joseph Kennedy

Journal of Medical Toxicology · 2021-10 · 17 (4) · 411-424

DOI: 10.1007/s13181-021-00833-8 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Medical Toxicology, online erschienen am 07.04.2021. Verfasst von Neeraj Chhabra und 1 weiteren Autor:innen. Beteiligte Einrichtung: Cook County Health, Department of Emergency Medicine, Division of Medical Toxicology, 1950 W Polk Street, 7th Floor, Chicago, IL, 60612, USA. NChhabr…. Hauptthemen laut MEDLINE: Drug-Related Side Effects and Adverse Reactions, Neoplasms. Die Arbeit wurde bisher 136-mal zitiert (Crossref) und nennt 149 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer immunotherapy, which leverages features of the immune system to target neoplastic cells, has revolutionized the treatment of cancer. The use of these therapies has rapidly expanded in the past two decades. Immune checkpoint inhibitors represent one drug class within immunotherapy with its first agent FDA-approved in 2011. Immune checkpoint inhibitors act by disrupting inhibitory signals from neoplastic cells to immune effector cells, allowing activated T-cells to target these neoplastic cells. Unique adverse effects associated with immune checkpoint inhibitors are termed immune-related adverse effects (irAEs) and are usually immunostimulatory in nature. Almost all organ systems may be affected by irAEs including the dermatologic, gastrointestinal, pulmonary, endocrine, and cardiovascular systems. These effects range from mild to life-threatening, and their onset can be delayed several weeks or months. For mild irAEs, symptomatic care is usually sufficient. For higher grade irAEs, discontinuation of therapy and initiation of immunosuppressive therapy may be necessary. The management of patients with irAEs involves multidisciplinary care coordination with respect to the long-term goals the individual patient. Clinicians must be aware of the unique and sometimes fatal toxicologic profiles associated with immunotherapies to ensure prompt diagnosis and appropriate management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug-Related Side Effects and Adverse ReactionsNeoplasmsHumansImmune Checkpoint InhibitorsImmunotherapy

Stichwörter der Autor:innen

Adverse eventsCheckpoint inhibitorChemotherapyImmunotherapyToxicity

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Cook County Health, Department of Emergency Medicine, Division of Medical Toxicology, 1950 W Polk Street, 7th Floor, Chicago, IL, 60612, USA. NChhabra@cookcountyhhs.org.
  • Toxikon Consortium, Chicago, IL, USA. NChhabra@cookcountyhhs.org.
  • Cook County Health, Department of Emergency Medicine, Division of Medical Toxicology, 1950 W Polk Street, 7th Floor, Chicago, IL, 60612, USA.
  • Toxikon Consortium, Chicago, IL, USA.

ORCID-Profile: Neeraj Chhabra

Zitieren

APA

Chhabra, N., & Kennedy, J. (2021). A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors. Journal of Medical Toxicology, 17(4), 411-424. https://doi.org/10.1007/s13181-021-00833-8

Vancouver

Chhabra N, Kennedy J. A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors. Journal of Medical Toxicology. 2021;17(4):411-424. doi:10.1007/s13181-021-00833-8

BibTeX
@article{Chhabra2021,
  author = {Chhabra, Neeraj and Kennedy, Joseph},
  title = {A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors},
  journal = {Journal of Medical Toxicology},
  year = {2021},
  volume = {17},
  number = {4},
  pages = {411--424},
  doi = {10.1007/s13181-021-00833-8}
}
Kostenlos starten →